1. Indications and Usage
\nTreatment of Chronic Hepatitis C Virus (HCV) Infection:
\nIndicated for the treatment of adult and pediatric patients (3 years of age and older and weighing at least 15 kg) with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).
\nDecompensated Cirrhosis:
\nIndicated for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection and decompensated cirrhosis (Child-Pugh B), to be used in combination with ribavirin.
\n2. Dosage and Administration
\nRecommended Dosage:
\nAdults and Adolescents (\u226512 years or \u226535 kg): One tablet (400 mg sofosbuvir and 100 mg velpatasvir) orally once daily.
\nTreatment Duration: Typically 12 weeks for patients without cirrhosis or with compensated cirrhosis. 12 weeks in combination with ribavirin for patients with decompensated cirrhosis.
\nAdministration Instructions:
\nCan be taken with or without food.
\nSwallow the tablet whole; do not chew or crush.
\nMissed Dose:
\nIf a dose is missed and it is less than 18 hours since the usual time of dosing, take the dose as soon as possible and resume the normal schedule.
\nIf more than 18 hours have passed, skip the missed dose and resume the normal schedule. Do not take a double dose.
\n3. Mechanism of Action
\nDirect-Acting Antiviral (DAA) Combination:
\nSofosbuvir and velpatasvir are direct-acting antiviral agents that target different steps in the HCV life cycle.
\nSofosbuvir:
\nA nucleotide analog inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is essential for viral replication.
\nVelpatasvir:
\nAn HCV NS5A (non-structural protein 5A) inhibitor, which is required for viral RNA replication and virion assembly.
\nPan-Genotypic Activity:
\nThe combination provides a pangenotypic treatment regimen, effective against all major HCV genotypes (1-6).
\n4. Safety and Warnings
\nHepatitis B Virus (HBV) Reactivation:
\nTest all patients for evidence of current or prior HBV infection before initiating treatment. HBV reactivation has been reported in patients coinfected with HCV and HBV who were treated with HCV direct-acting antivirals.
\nBradycardia with Concomitant Amiodarone:
\nSerious symptomatic bradycardia may occur in patients taking amiodarone concomitantly with sofosbuvir-containing regimens. Concomitant use is not recommended.
\nPost-Treatment Safety Monitoring:
\nPatients should be monitored for adverse events after treatment is completed.
\nPregnancy and Lactation:
\nIf co-administered with ribavirin, the pregnancy precautions and contraindications for ribavirin apply.
\n5. Adverse Reactions
\nMost Common:
\nFatigue, headache, nausea, diarrhea, and insomnia.
\nOther:
\nElevated bilirubin, anemia (when combined with ribavirin), and increased hepatic enzymes.
\n6. Drug Interactions
\nP-glycoprotein (P-gp) and CYP Inducers:
\nConcomitant use with strong P-gp inducers (e.g., rifampin, St. John’s wort) or potent CYP inducers (e.g., carbamazepine, phenytoin) is contraindicated as it significantly decreases sofosbuvir and velpatasvir plasma concentrations.
\nAcid-Reducing Agents:
\nVelpatasvir solubility decreases as pH increases. Concomitant use with proton pump inhibitors (PPIs) or H2-receptor antagonists may decrease velpatasvir plasma concentrations. Follow specific dosing separation recommendations.
\nStatins:
\nConcomitant use may increase plasma concentrations of certain statins (e.g., rosuvastatin), increasing the risk of myopathy.
\nAmiodarone:
\nSerious symptomatic bradycardia may occur. Concomitant use is not recommended.
\n7. Pharmaceutical Information
\nChemical Name:
\nSofosbuvir: Isopropyl (2S)-2-[[[(2R,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate.
\nVelpatasvir: (11S,16B,21aS,24aR)-11-(acetyloxy)-24a-(4-(4-((2-(bis(4-chlorophenyl)methoxy)ethyl)amino)-1,3,5-triazin-2-yl)phenyl)-16-(3-(3-fluorophenyl)oxetan-3-yl)-5-chloro-21a-methyl-11,14,19,22-tetraoxo-13,16-diazatetracyclo<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u4e19\u901a\u6c99 \u00ae(Epclusa\u00ae)
\nGeneric Name: Sofosbuvir and Velpatasvir
\nStrength: Each tablet contains 400 mg sofosbuvir and 100 mg velpatasvir, 28 tablets per bottle\/box
\nManufacturer: Gilead Sciences Ireland UC
\nMarketing Authorization Holder: Gilead Sciences, Inc.; Domestic responsible party: Gilead Sciences (Shanghai) Co., Ltd.
\nApproval Date in China: May 30, 2018
\nRegistration Number:\u56fd\u836f\u51c6\u5b57 H20180024
\nStorage: Store sealed below 30\u00b0C, avoid moisture; keep out of sight and reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Sofosbuvir and Velpatasvir\uff08Epclusa\uff09<\/p>\n","protected":false},"featured_media":3106,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3105","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n